InicioEVGN • NASDAQ
add
Evogene Ltd
Cierre anterior
1,60 $
Intervalo diario
1,49 $ - 1,62 $
Intervalo anual
1,44 $ - 10,40 $
Cap. bursátil
7,94 M USD
Volumen medio
557,75 mil
Relación precio-beneficio
-
Rentabilidad por dividendo
-
Bolsa de valores principal
NASDAQ
Noticias sobre los mercados
Datos financieros
Estado de resultados
Ingresos
Ingresos netos
(USD) | sept 2024info | Cambio interanual |
---|---|---|
Ingresos | 1,80 M | -52,32 % |
Gastos operativos | 8,17 M | 9,83 % |
Ingresos netos | -7,63 M | -91,52 % |
Margen de beneficio neto | -424,83 | -301,69 % |
Beneficios por acción | -1,31 | -63,75 % |
EBITDA | -6,83 M | -93,87 % |
Tipo impositivo efectivo | -0,01 % | — |
Balance general
Activos totales
Responsabilidades totales
(USD) | sept 2024info | Cambio interanual |
---|---|---|
Efectivo y a corto plazo | 19,95 M | -46,40 % |
Activos totales | 40,11 M | -30,53 % |
Responsabilidades totales | 27,88 M | 27,39 % |
Patrimonio total | 12,24 M | — |
Acciones en circulación | 6,79 M | — |
Precio-valor contable | -2,50 | — |
Rentabilidad económica | -45,97 % | — |
Retorno sobre capital | -110,69 % | — |
Flujo de caja
Variación neta del flujo de caja
(USD) | sept 2024info | Cambio interanual |
---|---|---|
Ingresos netos | -7,63 M | -91,52 % |
Efectivo de operaciones | -4,93 M | -14,15 % |
Efectivo de inversión | 2,02 M | -44,68 % |
Efectivo de financiación | 4,73 M | -39,30 % |
Variación neta del flujo de caja | 1,83 M | -74,18 % |
Flujo de caja libre | 1,24 M | 140,67 % |
Información sobre la empresa
Evogene is a computational biology company based in Israel. Evogene Ltd. has developed a unique computational predictive biology "CPB" platform, which leverages big data with advanced algorithms such as machine learning and other artificial intelligence, while adding a deep understanding of biology and advanced biological technologies. Evogene is using its proprietary CPB platform to computationally design and develop next-generation life-science products based upon three core components: microbes, small molecules, and genetic elements.
Evogene's computational platform allows it to substantially increase the probability of successful life-science product development, increase the efficiency and reduce the toxicity of its life-science products while reducing time and cost to development. Its strategic partners include BASF, Bayer, Corteva, ICL Group Ltd. as well as various academic and medical institutions. Wikipedia
Director ejecutivo
Fundación
2002
Sitio web
Empleados
142